EP1986674A4 - Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung - Google Patents

Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung

Info

Publication number
EP1986674A4
EP1986674A4 EP07750726A EP07750726A EP1986674A4 EP 1986674 A4 EP1986674 A4 EP 1986674A4 EP 07750726 A EP07750726 A EP 07750726A EP 07750726 A EP07750726 A EP 07750726A EP 1986674 A4 EP1986674 A4 EP 1986674A4
Authority
EP
European Patent Office
Prior art keywords
methionine
making
methods
containing protein
peptide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07750726A
Other languages
English (en)
French (fr)
Other versions
EP1986674A2 (de
Inventor
Thomas E Tarara
Cynthia Stevenson
Stewart Thompson
Reinhard Vehring
Negar Sadrzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of EP1986674A2 publication Critical patent/EP1986674A2/de
Publication of EP1986674A4 publication Critical patent/EP1986674A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP07750726A 2006-02-13 2007-02-13 Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung Withdrawn EP1986674A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77338406P 2006-02-13 2006-02-13
PCT/US2007/003905 WO2007095288A2 (en) 2006-02-13 2007-02-13 Methionine-containing protein or peptide compositions and methods of making and using

Publications (2)

Publication Number Publication Date
EP1986674A2 EP1986674A2 (de) 2008-11-05
EP1986674A4 true EP1986674A4 (de) 2009-11-11

Family

ID=38372110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07750726A Withdrawn EP1986674A4 (de) 2006-02-13 2007-02-13 Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung

Country Status (2)

Country Link
EP (1) EP1986674A4 (de)
WO (1) WO2007095288A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1933863A4 (de) * 2005-09-06 2010-06-09 Zelos Therapeutics Inc Parathyroid-hormonanaloge und verwendungsverfahren dafür
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
FR2954325B1 (fr) * 2009-12-23 2012-02-03 Flamel Tech Sa Polymere amphiphile fonctionnalise par la methionine
EP2364690A1 (de) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Oral verabreichbare pharmazeutische Tablette des epidermalen Wachstumsfaktors
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108195965B (zh) * 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
LT2739268T (lt) * 2011-08-01 2019-03-25 Monash University Inhaliacijos būdas ir kompozicija
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
LT2968466T (lt) * 2013-03-13 2018-10-10 F. Hoffmann-La Roche Ag Sumažintos oksidacijos kompozicijos
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
BR112017008923A2 (pt) 2014-10-31 2017-12-26 Glaxosmithkline Ip Dev Ltd ?formulação em pó?
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (en) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (en) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat

Also Published As

Publication number Publication date
EP1986674A2 (de) 2008-11-05
WO2007095288A3 (en) 2008-07-03
WO2007095288A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
EP1986674A4 (de) Methioninhaltige protein- oder peptidzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
IL262205A (en) Protein formulations and methods for their preparation
HK1249115A1 (zh) 肽序列和組合物
HK1216486A1 (zh) 蛋白飲料及其製備方法
HK1122196A1 (en) Protein hydrolysates and method of making
EP2102355A4 (de) Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
IL209386A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1987068A4 (de) Modifizierung von oligosacchariden und etikettierung von proteinen
PL1940240T3 (pl) Kompozycje izolatu białka i ich zastosowania
IL190748A0 (en) Methods and compositions comprising non-natural amino acids
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2029799A4 (de) Thermisch stabile proteine und verfahren zu ihrer herstellung und verwendung
EP2109673A4 (de) Verfahren und vorrichtung für verstärkte protein-expression und -reinigung
EP2234636A4 (de) Stabilisierte peptid- und proteinformulierungen
EP1998790A4 (de) Zusammensetzungen mit peptiden mit nicht-natürlichen aminosäuren und verwendungsverfahren
EP1789066A4 (de) Zusammensetzungen und verfahren zur verwendung von alpha-fetoprotein-wachstumshemmungspeptiden
PL2392587T3 (pl) Sekwencje i kompozycje peptydów
AU2006901628A0 (en) Site-selective derivatisation of peptides and proteins
GB0614260D0 (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions
GB0602416D0 (en) Peptide sequences and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TARARA, THOMAS, E.

Inventor name: STEVENSON, CYNTHIA

Inventor name: THOMPSON, STEWART

Inventor name: VEHRING, REINHARD

Inventor name: SADRZADEH, NEGAR

A4 Supplementary search report drawn up and despatched

Effective date: 20091014

17Q First examination report despatched

Effective date: 20100209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100820